Board Member
Cartesian Therapeutics, Inc. (RNAC)Equibles does not estimate personal net worth.
Get an email with a short summary when Cartesian Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get RNAC alertsCarsten Brunn is recorded as Board Member at Cartesian Therapeutics, Inc. (RNAC) since January 1, 2018 and CEO at Cartesian Therapeutics, Inc. (RNAC). The newest filing on record that lists Carsten Brunn as CEO and Board Member at Cartesian Therapeutics, Inc. (RNAC) is dated April 28, 2026. The proxy statement of Cartesian Therapeutics, Inc. reports total compensation of $4,329,868 for Carsten Brunn in fiscal 2025, including a base salary of $674,000. Disclosed compensation is on record for 8 fiscal years. Carsten Brunn has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for Cartesian Therapeutics, Inc. on May 19, 2026. Cartesian Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cartesian Therapeutics, Inc. includes Carsten Brunn, Ph.D. (Chairman), Blaine Davis (CFO and Chief Accounting Officer), Kevin Tan (CFO) and 7 others.
“So maybe for those in the room who are not up to speed on the Cartesian story, you could provide a brief overview of the current pipeline and the current efforts for Cartesian. yeah so thanks for the opportunity so we were an mrna carty company focused exclusively on autoimmune disease late-stage clinical phase three…”
“So Cartesian is an mRNA cell therapy company focused exclusively on autoimmune disease. Our lead asset, Deckard 8, is currently in a phase three in Myosinia Gravis.”
“So Cartesian is an mRNA cell therapy company focused exclusively on autoimmune disease. Our lead asset, Deckard 8, is currently in a phase three in Myosinia Gravis.”
2018-01-01–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CEO, Board Member
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $674,000 | $4,329,868 |
| 2024 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $642,720 | $7,314,211 |
| 2023 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $618,228 | $6,111,883 |
| 2022 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $588,043 | $4,292,242 |
| 2021 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $569,003 | $3,671,395 |
| 2020 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $550,000 | $2,095,347 |
| 2019 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $550,000 | $1,986,495 |
| 2018 | Cartesian Therapeutics, Inc. (RNAC) | President and Chief Executive Officer | $42,308 | $5,605,148 |
